FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016867963> ?p ?o ?g. }

• W3016867963 endingPage "843" @default.
• W3016867963 startingPage "841" @default.
• W3016867963 abstract "During the current coronavirus disease 2019 (COVID-19) pandemic, several questions have arisen relating to the management of pregnant women. The risk of COVID-19 to pregnant women may be much lower than in the previous SARS epidemic. The case fatality rates (CFR) in pregnant women during the SARS and MERS epidemics were 15% and 27%, respectively1, 2, while COVID-19 seems to have a milder natural history2. The available data regarding COVID-19 are limited; therefore, maternal outcomes may be underreported at present. Published observations in non-pregnant patients have shown that non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, can cause progression of pulmonary disease. This relationship has been observed in bacterial pulmonary infections. Experimental data suggest that NSAIDs alter the function of neutrophils and delay bacterial clearance and inflammation resolution3, 4. Observational data suggest an association between exposure to NSAIDs and the occurrence of pleuropulmonary complications (pleural empyema, excavation and abscess). Similar observations have also been made in a small group of young people taking ibuprofen for COVID-19 symptoms3, 4. As a result, French health officials have issued a precaution regarding the use of NSAIDs, including aspirin. This has started an international debate among healthcare professionals regarding the usage of NSAIDs, primarily ibuprofen, in patients with COVID-195. The Spanish Ministry of Health has stated that there is no evidence that ibuprofen (or other NSAIDs) could worsen SARS-CoV-2 infection. However, it stated that ibuprofen might mask the symptoms of infection, therefore delaying diagnosis6. The Royal College of Obstetricians and Gynaecologists in the UK recommends paracetamol for COVID-19 symptoms7. There is therefore cause for concern regarding the wellbeing of pregnant women taking aspirin for prophylaxis of pre-eclampsia and fetal growth restriction. The debate could have resulted in a misunderstanding among both healthcare professionals and pregnant women, leading to withdrawal of prophylactic low-dose aspirin therapy. Currently, there are no available data regarding the association between the risk of COVID-19 progression and intake of low-dose aspirin. Pre-eclampsia affects 2–8% of pregnancies worldwide and is one of the leading causes of maternal death and perinatal mortality and morbidity8. Currently, around the world, there are more than 350 536 active cases of COVID-19 and this number is increasing every day9. On the other hand, there are fewer than 100 published cases of COVID-19 in pregnant women. Based on these case series and reports, it appears that the natural history of SARS-CoV-2 infection among pregnant women is not different from that in non-pregnant adults. A World Health Organization (WHO) report from China states that only 1% of the described cases in pregnant women have been critical and 8% were severe10. At the time of writing, there were no reported maternal deaths related to SARS-CoV-2 infection. None of the cases of COVID-19 in pregnant women in the series of Schwartz was severe11. Low-dose aspirin has been proven to be an effective regimen for the prevention of placental complications during pregnancy, including pre-eclampsia and fetal growth restriction. Intake of low-dose aspirin during pregnancy is not associated with an increased risk of congenital defects, bleeding or premature closure of the ductus arteriosus8. The recommended dosage of 150 mg of aspirin daily for the prevention of pre-eclampsia is based on the results of the ASPRE trial. In the trial, preterm pre-eclampsia occurred in 1.6% of women in the low-dose aspirin group, as compared with 4.3% in the placebo group (odds ratio, 0.38; 95% CI, 0.20–0.74; P = 0.004)8. The WHO has published an official statement recommending not to avoid the use of ibuprofen based on the current available data12. To our knowledge, there are limited data to suggest that there is an association between prophylactic use of low-dose aspirin and increased risk of progression of SARS-CoV-2 infection. In our opinion, during the COVID-19 pandemic, it is still essential to provide first-trimester screening for placental complications and to prescribe low-dose aspirin in women who are identified as high risk for pre-eclampsia and fetal growth restriction. Based on the current knowledge of the epidemiological situation, the benefits of placental complication prevention outweigh the potential risks of adverse outcome related to the usage of low-dose aspirin in patients with SARS-CoV-2 infection." @default.
• W3016867963 created "2020-04-24" @default.
• W3016867963 creator A5006015096 @default.
• W3016867963 creator A5006135773 @default.
• W3016867963 creator A5006480135 @default.
• W3016867963 creator A5016652536 @default.
• W3016867963 creator A5040828170 @default.
• W3016867963 creator A5059647833 @default.
• W3016867963 date "2020-06-01" @default.
• W3016867963 modified "2023-10-16" @default.
• W3016867963 title "Why we should not stop giving aspirin to pregnant women during the COVID‐19 pandemic" @default.
• W3016867963 cites W2738449290 @default.
• W3016867963 cites W2802130756 @default.
• W3016867963 cites W3004581842 @default.
• W3016867963 cites W3010928971 @default.
• W3016867963 cites W3011386994 @default.
• W3016867963 cites W3011558436 @default.
• W3016867963 cites W3011957742 @default.
• W3016867963 doi "https://doi.org/10.1002/uog.22049" @default.
• W3016867963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7264504" @default.
• W3016867963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32304612" @default.
• W3016867963 hasPublicationYear "2020" @default.
• W3016867963 type Work @default.
• W3016867963 sameAs 3016867963 @default.
• W3016867963 citedByCount "24" @default.
• W3016867963 countsByYear W30168679632020 @default.
• W3016867963 countsByYear W30168679632021 @default.
• W3016867963 countsByYear W30168679632022 @default.
• W3016867963 countsByYear W30168679632023 @default.
• W3016867963 crossrefType "journal-article" @default.
• W3016867963 hasAuthorship W3016867963A5006015096 @default.
• W3016867963 hasAuthorship W3016867963A5006135773 @default.
• W3016867963 hasAuthorship W3016867963A5006480135 @default.
• W3016867963 hasAuthorship W3016867963A5016652536 @default.
• W3016867963 hasAuthorship W3016867963A5040828170 @default.
• W3016867963 hasAuthorship W3016867963A5059647833 @default.
• W3016867963 hasBestOaLocation W30168679631 @default.
• W3016867963 hasConcept C126322002 @default.
• W3016867963 hasConcept C138885662 @default.
• W3016867963 hasConcept C141071460 @default.
• W3016867963 hasConcept C23131810 @default.
• W3016867963 hasConcept C27206212 @default.
• W3016867963 hasConcept C2777628954 @default.
• W3016867963 hasConcept C2777799383 @default.
• W3016867963 hasConcept C2779134260 @default.
• W3016867963 hasConcept C2779944601 @default.
• W3016867963 hasConcept C3008058167 @default.
• W3016867963 hasConcept C521751864 @default.
• W3016867963 hasConcept C524204448 @default.
• W3016867963 hasConcept C71924100 @default.
• W3016867963 hasConcept C89623803 @default.
• W3016867963 hasConcept C98274493 @default.
• W3016867963 hasConceptScore W3016867963C126322002 @default.
• W3016867963 hasConceptScore W3016867963C138885662 @default.
• W3016867963 hasConceptScore W3016867963C141071460 @default.
• W3016867963 hasConceptScore W3016867963C23131810 @default.
• W3016867963 hasConceptScore W3016867963C27206212 @default.
• W3016867963 hasConceptScore W3016867963C2777628954 @default.
• W3016867963 hasConceptScore W3016867963C2777799383 @default.
• W3016867963 hasConceptScore W3016867963C2779134260 @default.
• W3016867963 hasConceptScore W3016867963C2779944601 @default.
• W3016867963 hasConceptScore W3016867963C3008058167 @default.
• W3016867963 hasConceptScore W3016867963C521751864 @default.
• W3016867963 hasConceptScore W3016867963C524204448 @default.
• W3016867963 hasConceptScore W3016867963C71924100 @default.
• W3016867963 hasConceptScore W3016867963C89623803 @default.
• W3016867963 hasConceptScore W3016867963C98274493 @default.
• W3016867963 hasIssue "6" @default.
• W3016867963 hasLocation W30168679631 @default.
• W3016867963 hasLocation W30168679632 @default.
• W3016867963 hasLocation W30168679633 @default.
• W3016867963 hasOpenAccess W3016867963 @default.
• W3016867963 hasPrimaryLocation W30168679631 @default.
• W3016867963 hasRelatedWork W1986665418 @default.
• W3016867963 hasRelatedWork W2001431596 @default.
• W3016867963 hasRelatedWork W2042227405 @default.
• W3016867963 hasRelatedWork W2047402016 @default.
• W3016867963 hasRelatedWork W2055466697 @default.
• W3016867963 hasRelatedWork W2081310581 @default.
• W3016867963 hasRelatedWork W2084328926 @default.
• W3016867963 hasRelatedWork W2106346422 @default.
• W3016867963 hasRelatedWork W2134499965 @default.
• W3016867963 hasRelatedWork W2907769512 @default.
• W3016867963 hasVolume "55" @default.
• W3016867963 isParatext "false" @default.
• W3016867963 isRetracted "false" @default.
• W3016867963 magId "3016867963" @default.
• W3016867963 workType "article" @default.